ATRX mRNA expression combined with IDH1/2 mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: evidence from the whole transcriptome sequencing of 169 samples samples.

ATRX mRNA expression combined with IDH1/2 mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: evidence from the whole transcriptome sequencing of 169 samples samples.

Item

http://www.wikidata.org/entity/Q33757037

Q33757037

about

Molecular Markers in Low-Grade Glioma-Toward Tumor Reclassification HDAC4, a prognostic and chromosomal instability marker, refines the predictive value of MGMT promoter methylation.IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas.Identification of a 6-cytokine prognostic signature in patients with primary glioblastoma harboring M2 microglia/macrophage phenotype relevance.Genetic and clinical characteristics of primary and secondary glioblastoma is associated with differential molecular subtype distribution ALDH1A3: A Marker of Mesenchymal Phenotype in Gliomas Associated with Cell Invasion Comparative Analysis of Matrix Metalloproteinase Family Members Reveals That MMP9 Predicts Survival and Response to Temozolomide in Patients with Primary Glioblastoma.Integrated analysis of genome-wide DNA methylation, gene expression and protein expression profiles in molecular subtypes of WHO II-IV gliomas.Loss of ATRX, associated with DNA methylation pattern of chromosome end, impacted biological behaviors of astrocytic tumors.IDH1/2 mutation status combined with Ki-67 labeling index defines distinct prognostic groups in glioma.Detection of ATRX and IDH1-R132H immunohistochemistry in the progression of 211 paired gliomas ATRX, IDH1-R132H and Ki-67 immunohistochemistry as a classification scheme for astrocytic tumors.IDH-1R132H mutation status in diffuse glioma patients: implications for classification GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment.Phosphohistone H3 (pHH3) is a prognostic and epithelial to mesenchymal transition marker in diffuse gliomas.Anaplastic glioma: current treatment and management.The Diagnostic Use of Immunohistochemical Surrogates for Signature Molecular Genetic Alterations in Gliomas.Evolving Molecular Genetics of Glioblastoma.CAMKK2, Regulated by Promoter Methylation, is a Prognostic Marker in Diffuse Gliomas.Bioinformatic Profiling Identifies a Glucose-Related Risk Signature for the Malignancy of Glioma and the Survival of Patients.Gene Expression Profiling Stratifies IDH1-Mutant Glioma with Distinct Prognoses.Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas Identification of epigenetic signature associated with alpha thalassemia/mental retardation X-linked syndrome.Gene Expression and Methylation Analyses Suggest DCTD as a Prognostic Factor in Malignant Glioma.Prognostic role of IDH mutations in gliomas: a meta-analysis of 55 observational studies.Epigenetic silencing of miR-338 facilitates glioblastoma progression by de-repressing the pyruvate kinase M2-β-catenin axis.ATRX immunostaining predicts IDH and H3F3A status in gliomas.Molecular classification defines 4 prognostically distinct glioma groups irrespective of diagnosis and grade.Immunohistochemistry on IDH 1/2, ATRX, p53 and Ki-67 substitute molecular genetic testing and predict patient prognosis in grade III adult diffuse gliomas.IDH1 status is significantly different between high-grade thalamic and superficial gliomas.hTERT promoter methylation in meningiomas and central nervous hemangiopericytomas.Whole-exome sequencing identifies germline mutation in TP53 and ATRX in a child with genomically aberrant AT/RT and her mother with anaplastic astrocytoma.

P2860

Q28383205-B4E8E0B4-0FD2-4C6C-B671-DB527E90D786 Q35203538-D305A0BE-A210-43F1-BEA0-8E358A48909E Q35204658-D91B68B0-051F-494F-96F8-F67A54C42766 Q35610772-8B17E3A8-542F-4D6B-8B63-33E92B4B0974 Q35740211-01EDD02E-27BE-42A3-8AC9-52FF3EA589C1 Q35843516-042254D6-A623-4FA6-B3BD-B37DBA95BB66 Q35972486-10910A6B-F16E-4841-8E3D-08231B353EC6 Q36206332-83D2D67D-667A-4B85-8742-27ED5B1A5BD2 Q36228514-AB6D93A9-B46E-423D-93F6-F6CD49A92045 Q36557547-AC02E409-93BD-4084-84CC-A3FAFDC6D1B1 Q37086042-BC0121A0-31AF-490C-BB99-520640FF270B Q37298192-EB0830F6-862F-4C74-AA5A-BE2BE70C216D Q37327761-711E9D8A-CFCF-47C1-BEA3-9678A3BDDEED Q37450330-83ACA8F2-D720-4201-91F1-7A56CC32A2D1 Q37564326-6FE7ABD5-C517-4CA3-B912-2990F1D9EDD8 Q38456018-49F1A4AA-6887-4FC2-BB8A-3C9BC232DF06 Q38670567-8C2D6E9D-F981-49E7-AC19-C212FCA0EDE3 Q38734366-DAF1BCAD-6D8D-498F-AF31-05B243B77F89 Q38783297-ABA38070-106C-4D0F-87F6-76BD753AEA70 Q38789127-0DBC44C1-9BC1-4E06-AF2F-16FB5D163C46 Q39328886-6B2F3920-1E66-490A-A3A8-32BC599E4F12 Q39937053-C399EA81-D2E9-480F-B096-738BB944BFF3 Q40292496-187E3C95-4880-4FEC-9888-E45900F08FBD Q41044200-11CD0338-D24B-4535-A442-06710734ECA1 Q41536288-48E2CFA8-7A94-408B-B4B3-F52C6C95929C Q41669897-DF0B3C6C-DDF9-4E4F-A6E3-ED8BF18F2FC9 Q42701263-BFCBC6AC-36DB-49DB-8AD9-09089F26F48B Q48335626-B471319A-9D7D-4381-8DA2-70E9CAA58E23 Q48841420-685985A7-37C6-40C8-8FAD-D474C1D54174 Q50225580-82DBD0F5-B23F-453B-BD86-4381CE13FDC2 Q51612185-DBDD18F8-F089-4C93-A180-EE208F781C1A Q54958675-C66856B1-F197-45B0-9FB2-E80CE9E4B2AD

P2860

ATRX mRNA expression combined with IDH1/2 mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: evidence from the whole transcriptome sequencing of 169 samples samples.

Item

http://www.wikidata.org/entity/Q33757037

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu